Key result
Angiotensin II-increasing antihypertensives show no link to reduced ischemic stroke severity versus suppressors.
Why the study?
The neuroprotective properties of increased angiotensin II formation by selected antihypertensive drugs and their impact on ischemic stroke severity remain inconclusive.
Does the use of antihypertensive drugs that increase Ang II formation reduce ischemic stroke severity compared to those that suppress Ang II formation in hypertensive patients with first ischemic stroke?
Cross-Sectional (n=710)
Yes
Does the use of antihypertensive drugs that increase Ang II formation reduce ischemic stroke severity compared to those that suppress Ang II formation in hypertensive patients with first ischemic stroke?
Prior use of antihypertensive drugs that increase Ang II formation does not reduce ischemic stroke severity compared to drugs that suppress Ang II formation.
No association seen with stroke severity by drug class; leaves open need for prospective trials in hypertension.
BACKGROUND: The increase in angiotensin II (Ang II) formation by selected antihypertensive drugs is said to exhibit neuroprotective properties, but this translation into improvement in clinical outcomes has been inconclusive. We undertook a study to investigate the relationship between types of antihypertensive drugs used prior to a stroke event and ischemic stroke severity. We hypothesized that use of antihypertensive drugs that increase Ang II formation (Ang II increasers) would reduce ischemic stroke severity when compared to antihypertensive drugs that suppress Ang II formation (Ang II suppressors). METHODS: From the Malaysian National Neurology Registry, we included hypertensive patients with first ischemic stroke who presented within 48 hours from ictus. Antihypertensive drugs were divided into Ang II increasers (angiotensin-I receptor blockers (ARBs), calcium channel blockers (CCBs) and diuretics) and Ang II suppressors (angiotensin-converting-enzyme inhibitors (ACEIs) and beta blockers). We evaluated stroke severity during admission with the National Institute of Health Stroke Scale (NIHSS). We performed a multivariable logistic regression with the score being dichotomized at 15. Scores of less than 15 were categorized as less severe stroke. RESULTS: A total of 710 patients were included. ACEIs was the most commonly prescribed antihypertensive drug in patients using Ang II suppressors (74%) and CCBs, in patients prescribed with Ang II increasers at 77%. There was no significant difference in the severity of ischemic stroke between patients who were using Ang II increasers in comparison to patients with Ang II suppressors (OR: 1.32, 95%CI: 0.83-2.10, p = 0.24). CONCLUSION: In our study, we found that use of antihypertensive drugs that increase Ang II formation was not associated with less severe ischemic stroke as compared to use of antihypertensive drugs that suppress Ang II formation.
No takes yet. Share an insight, caveat, or question.
Hwong et al. (2016) conducted a cross-sectional in Ischemic stroke or transient ischemic attack (n=710). Antihypertensive drugs that increase Ang II formation (ARBs, CCBs, diuretics) vs. Antihypertensive drugs that suppress Ang II formation (ACEIs, beta blockers) was evaluated on Ischemic stroke severity (NIHSS score dichotomized at 15) (OR 1.32, 95% CI 0.83-2.10, p=0.24). Prior use of antihypertensive drugs that increase angiotensin II formation was not associated with less severe ischemic stroke compared to drugs that suppress its formation (OR 1.32).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: